SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: Facade of Moderna's building in Massachusetts
Layoffs
Moderna Slashes Global Workforce by 10% as $1.5B Cost Cuts Hit Home
The announced reduction of hundreds of staff came a day ahead of Moderna’s Q2 earnings report.
July 31, 2025
 · 
1 min read
 · 
Annalee Armstrong
Pictured: Eli Lilly's headquarters in Indianapolis
Diabetes
Lilly’s Mounjaro ‘Good Enough’ in Cardio Trial, Will Seek Expanded Approval
While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical significance in reducing major events such as cardiovascular death, heart attack and stroke.
July 31, 2025
 · 
2 min read
 · 
Heather McKenzie
Illustration of escape key in human hands
Job Trends
Greener Pastures? 81% of Employed Biopharma Professionals Want New Jobs, BioSpace Finds
Employed biopharma professionals are highly likely to look for new jobs in the next 12 months, although not quite as likely as their unemployed counterparts, according to a BioSpace LinkedIn poll. Three recruitment experts discuss the findings and what’s driving job searches.
July 31, 2025
 · 
4 min read
 · 
Angela Gabriel
IN PARTNERSHIP WITH IQVIA
We Don’t Own Patient Data–We’re Just Babysitting It
In this episode presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses the concerns and opportunities of patient data driving AI tasks with Louise Molloy, associate director medical information and pharmacovigilance.
July 31, 2025
 · 
1 min read
 · 
Lori Ellis
woman hand is removing hair from blue brush. A Hair care.
Immunology and inflammation
AbbVie Carves Out Niche for Rinvoq With ‘Impressive’ Alopecia Areata Data
Rinvoq’s efficacy in alopecia areata is “impressive,” according to Guggenheim analysts, who said the drug could have a competitive edge over other JAK inhibitors in the space.
July 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Female hand holds notebook with brain on yellow background
Alzheimer’s disease
Amyloid Return ‘Slow’ After Stopping Lilly’s Kisunla
Long-term extension data presented at the Alzheimer’s Association International Conference showed amyloid plaque reaccumulation remained slow at up to 2.5 years of follow-up in patients who were taken off of treatment with Eli Lilly’s anti-amyloid antibody.
July 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Raleigh, North Carolina, skyline
Job Trends
7 Companies Hiring in North Carolina
Looking for a biopharma job in North Carolina? Check out the BioSpace list of seven companies hiring life sciences professionals like you.
July 31, 2025
 · 
1 min read
 · 
Angela Gabriel
Illustration showing cyber money background
Job Trends
Amidst Industry Challenges, 85% of Pharmas Increase Investment in AI
A new report found that 85% of pharma respondents are increasing their artificial intelligence investments, and 70% see AI as an immediate priority. Two experts discuss how biopharmas are implementing and adopting AI, including their increased use of external help with the process.
July 31, 2025
 · 
4 min read
 · 
Angela Gabriel
FDA CDER director George Tidmarsh speaking in an FDA video
Government
New CDER Head Tidmarsh Will Sub In At Biologics Group After Prasad’s Exit
George Tidmarsh has only been at the Center for Drug Evaluation and Research for nine days, but will now add supervision of a second FDA division to his portfolio after Vinay Prasad’s sudden departure.
July 30, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS